Core Viewpoint - The recent surge in the stock price of Precision Medical-B (02675) is attributed to the announcement of a national pricing guideline for surgical robots and related medical services by the National Healthcare Security Administration, marking a significant turning point for the commercialization of the surgical robot industry [1] Group 1: Company Performance - Precision Medical-B's stock rose over 7% recently, following a previous increase of over 11%, with the current price at 70.95 HKD and a trading volume of 48.18 million HKD [1] - The company is recognized as one of the top two domestic surgical robot manufacturers, with rapid growth in multi-port and single-port laparoscopic robots, as well as natural orifice robots both domestically and internationally [1] Group 2: Industry Developments - The newly released pricing framework for robotic surgeries is expected to be a crucial event for the commercialization of the surgical robot industry [1] - According to Northeast Securities, Precision Medical is projected to lead in the number of successful bids for domestic laparoscopic robot procurement by 2025 [1] - The remote surgical procedure is anticipated to receive NMPA approval by November 2025, with a milestone of 500 surgeries expected to be achieved by October 2025 [1]